SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests how well SX-682 and atezolizumab works for the treatment of non-small cell lung cancer (NSCLC) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic), and has come back after a period of improvement (recurrent). SX-682 blocks proteins that may be able to stimulate the immune system to kill and eliminate tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving SX-682 and atezolizumab may be effective for the treatment of advanced or metastatic, recurrent NSCLC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat i więcej
- •Potwierdzony diagnozą rak płuca bez określonych mutacji genetycznych (EGFR, ALK, ROS1, RET)
- •Zaawansowany lub nawracający rak płuca, który rozprzestrzenił się na inne części ciała
- •Wcześniejsze leczenie immunoterapią (co najmniej 6 tygodni) dla zaawansowanego raka
- •Wcześniejsze leczenie chemioterapią opartą na platynie
- •Co najmniej 28 dni przerwy od ostatniej terapii przed rozpoczęciem badania
- •Zdolność do zrozumienia warunków badania i podpisania zgody
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 31, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Fred Hutch/University of Washington Cancer Consortium
Seattle, United States
Trial contact
Rebecca Wood
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/28/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.